Supernus completes acquisition of Sage Therapeutics for $8.50/share plus CVR

Sage Therapeutics, Inc.

Tender offer expired with 36.3M shares (58%) tendered; all conditions satisfied.
Shareholders receive $8.50 cash per share plus up to $3.50 per share CVR.
Shares to be delisted from Nasdaq; company will file Form 15 to terminate registration.
All prior directors and officers resigned; replaced by Supernus designees including Jack Khattar.
CEO Barry Greene's severance amended with 18-month pay and 24-month non-compete covenant.

item 2.01item 3.01item 5.01item 3.03item 5.03item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.